Edgewise Therapeutics, Inc. - EWTX STOCK NEWS

Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a clinical-stage biopharmaceutical company, announced participation in the SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines 1×1 Event on September 23, 2021. The senior management team will engage in one-on-one investor meetings during this event. Edgewise focuses on developing innovative, orally bioavailable therapies for rare muscle disorders. The company employs an advanced drug discovery platform aimed at addressing significant unmet medical needs in muscle biology.

Edgewise Therapeutics (NASDAQ: EWTX) announced the FDA has granted Fast Track designation for EDG-5506, aimed at treating Becker muscular dystrophy (BMD). This selective myosin inhibitor is currently in a Phase 1 clinical trial, with topline data expected later in 2021. The Fast Track designation emphasizes the urgent need for therapies addressing serious conditions like BMD, which affects roughly 4,000-5,000 individuals in the U.S. EDG-5506 seeks to offer a novel therapeutic option, targeting the underlying issues caused by dysfunctional dystrophin in muscle tissue.

Edgewise Therapeutics (NASDAQ: EWTX) reported its Q2 2021 financial results, highlighting ongoing clinical progress with EDG-5506, its lead candidate for treating Duchenne and Becker muscular dystrophies. Cash and equivalents stood at $299 million. R&D expenses surged to $7.9 million, primarily due to clinical trial advancements. Net loss reached $10.4 million ($0.21 per share), up from $4.0 million year-over-year. The company anticipates topline data from its Phase 1 trials by the end of 2021, focusing on establishing a new standard of care for severe muscle disorders.

Edgewise Therapeutics (NASDAQ: EWTX), a clinical-stage biopharmaceutical company, will participate in the virtual Wedbush PacGrow Healthcare Conference on August 11. Members of the management team will engage in a fireside chat at 3:30 PM ET, which will be streamed live and available for 90 days afterward. Edgewise specializes in developing innovative, orally bioavailable therapies for rare muscle disorders, leveraging its expertise in muscle biology and small molecule engineering to address significant unmet medical needs.

Edgewise Therapeutics (NASDAQ: EWTX), a clinical-stage biopharmaceutical company, announced its participation in two key conferences: the 2021 PPMD Annual Conference and the 2021 New Directions in Biology and Disease of Skeletal Muscle Conference.

The presentations will cover Edgewise's innovative therapies for Duchenne and Becker muscular dystrophies. Key speakers include Alan Russell, Ph.D., and Joanne Donovan, M.D., with sessions on June 23 and June 28, 2021, respectively. The talks will be available on the Edgewise website post-event.

Edgewise Therapeutics (NASDAQ: EWTX) announced participation in the virtual Goldman Sachs 42nd Annual Global Healthcare Conference on June 9, 2021, at 5:30 p.m. ET. Members of the management team will engage in a fireside chat and one-on-one investor meetings. The webcast will be available live through the investor relations section of Edgewise’s website and can be accessed for 90 days post-event. Edgewise focuses on developing innovative therapies for rare muscle disorders, leveraging its expertise in muscle biology and small molecule engineering.

Edgewise Therapeutics (EWTX) reported its Q1 2021 financial results, highlighting a successful IPO that raised $202.4 million. The proceeds bolster the advancement of their lead candidate, EDG-5506, targeting rare muscle disorders like DMD and BMD. The firm expects to release topline data from clinical trials later in 2021. R&D expenses rose to $5.4 million due to increased trials and staffing, while G&A expenses increased to $1.5 million. The net loss for the quarter was $6.8 million, translating to a net loss per share of $4.37. Cash reserves stood at $309.9 million.

Edgewise Therapeutics (NASDAQ: EWTX) announced the publication of a retrospective study highlighting elevated fast muscle fiber injury biomarkers in Becker and Duchenne muscular dystrophy (BMD, DMD) patients. This research suggests that fast skeletal troponin I (TNNI2) may be a more sensitive biomarker of muscle injury than creatine kinase (CK). These findings support the development of EDG-5506, a candidate designed to protect fast muscle fibers. This study advances the understanding of muscle injury biomarkers in BMD and DMD, indicating a significant step in clinical development.

Edgewise Therapeutics (NASDAQ: EWTX) has appointed Dr. Joanne M. Donovan as Chief Medical Officer, aiming to bolster its clinical and regulatory strategies for its lead product, EDG-5506, targeting Duchenne and Becker muscular dystrophy (DMD and BMD). Dr. Donovan brings extensive experience in rare disease clinical development, having previously led programs from discovery to approval. EDG-5506 represents a novel treatment approach for these muscle disorders, currently in Phase 1 clinical trials, with topline data expected soon.